SEC Form 4 · accession 0001325812-18-000004
ALNYLAM PHARMACEUTICALS, INC. · ALNY
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael Mason
Officer — VP, Finance and Treasurer
Period of report
Jan 4, 2018
Accepted (ET)
Jan 8, 2018 · 5:02 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001178670
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jan 4, 2018 | M | 1,388 | $42.22 | A | 6,352 | D | |
| Common Stock | Jan 4, 2018 | M | 1,667 | $63.00 | A | 8,019 | D | |
| Common Stock | Jan 4, 2018 | M | 3,600 | $88.95 | A | 11,619 | D | |
| Common Stock | Jan 4, 2018 | M | 2,750 | $96.45 | A | 14,369 | D | |
| Common Stock | Jan 4, 2018 | M | 2,750 | $96.45 | A | 17,119 | D | |
| Common Stock | Jan 4, 2018 | M | 10,000 | $97.72 | A | 27,119 | D | |
| Common Stock | Jan 4, 2018 | M | 6,187 | $96.45 | A | 33,306 | D | |
| Common Stock | Jan 4, 2018 | M | 3,439 | $63.00 | A | 36,745 | D | |
| Common StockF2 | Jan 4, 2018 | S | 5,249 | $130.42 | D | 31,496 | D | |
| Common StockF3 | Jan 4, 2018 | S | 16,500 | $131.20 | D | 14,996 | D | |
| Common StockF4 | Jan 4, 2018 | S | 12,405 | $132.18 | D | 2,591 | D | |
| Common StockF5 | Jan 4, 2018 | S | 1,591 | $132.98 | D | 1,000 | D | |
| Common StockF6 | Jan 4, 2018 | S | 400 | $133.83 | D | 600 | D | |
| Common StockF7 | Jan 4, 2018 | S | 600 | $135.00 | D | 0 | D | |
| Common StockF8 | holding | — | — | — | 226 | I | by Managed Account |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Performance Stock Option 2013 (right to buy) | $63.00 | Jan 4, 2018 | M | 1,667 | D | Sep 20, 2017 | Dec 17, 2023 | Common Stock | 1,667 | 0 | D |
| Performance Stock Option 2014 (right to buy) | $96.45 | Jan 4, 2018 | M | 2,750 | D | Feb 1, 2016 | Dec 17, 2024 | Common Stock | 2,750 | 2,750 | D |
| Performance Stock Option 2014 (right to buy) | $96.45 | Jan 4, 2018 | M | 2,750 | D | Jul 7, 2017 | Dec 17, 2024 | Common Stock | 2,750 | 0 | D |
| Stock Option (right to buy)F9 | $42.22 | Jan 4, 2018 | M | 1,388 | D | — | Dec 20, 2026 | Common Stock | 1,388 | 4,162 | D |
| Stock Option (right to buy)F9 | $63.00 | Jan 4, 2018 | M | 3,439 | D | — | Dec 18, 2023 | Common Stock | 3,439 | 0 | D |
| Stock Option (right to buy)F9 | $88.95 | Jan 4, 2018 | M | 3,600 | D | — | Dec 18, 2025 | Common Stock | 3,600 | 3,600 | D |
| Stock Option (right to buy)F9 | $96.45 | Jan 4, 2018 | M | 6,187 | D | — | Dec 17, 2024 | Common Stock | 6,187 | 2,063 | D |
| Stock Option (right to buy) | $97.72 | Jan 4, 2018 | M | 10,000 | D | Dec 7, 2015 | Dec 7, 2025 | Common Stock | 10,000 | 0 | D |
Explanation of responses
- F1All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 2, 2017.
- F2Sale prices ranged from $129.74 to $130.72.
- F3Sale prices ranged from $130.74 to $131.73.
- F4Sale prices ranged from $131.75 to $132.71.
- F5Sale prices ranged from $132.75 to $133.71.
- F6Sale prices ranged from $133.78 to $134.11.
- F7Sale prices ranged from $134.94 to $135.10
- F8The reporting person owns 226 shares of ALNY common stock under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program.
- F9The stock option vests as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter.